| Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 |
|---|
| Net Income From Continuing Operations | 1,351 | 917 | 1,023 |
|---|
| Depreciation | 92 | 96 | 120 |
|---|
| Amortization | 103 | 116 | 116 |
|---|
| Impairment of assets | 7 | 9 | - |
|---|
| Research and Development in Process | 104 | 107 | - |
|---|
| Acquired in-process research and development and milestones | - | - | 8 |
|---|
| Deferred income taxes | -288 | -18 | -485 |
|---|
| Stock-based compensation | 59 | 75 | 101 |
|---|
| Unrealized foreign exchange loss (gain) | - | 18 | -40 |
|---|
| Other | -12 | -26 | -31 |
|---|
| Accounts receivable | 277 | 123 | 212 |
|---|
| Inventories | 138 | 220 | 230 |
|---|
| Other current assets | -353 | 43 | 10 |
|---|
| Trade accounts payable | 663 | -237 | 163 |
|---|
| Accrued and other current liabilities | 329 | 172 | 102 |
|---|
| Due from/due to related party | -164 | - | - |
|---|
| Income taxes payable | -119 | 7 | 16 |
|---|
| Other | -55 | 8 | -16 |
|---|
| Net Cash Flows Provided by Operating Activities from Continuing Operations | 2,160 | 858 | 799 |
|---|
| Capital expenditures | 192 | 196 | 251 |
|---|
| Proceeds from sale of property, plant and equipment | 7 | 7 | 1 |
|---|
| Acquired in-process research and development and milestones | 104 | 107 | 8 |
|---|
| Purchase of product rights and asset acquisition, net of cash acquired | 192 | 124 | 2 |
|---|
| Net Cash Flows Used in Investing Activities from Continuing Operations | -481 | -420 | -260 |
|---|
| Proceeds from debt | 9,470 | - | 80 |
|---|
| Repayments of debt | 112 | 108 | 338 |
|---|
| Payment of long-term debt issuance costs | 118 | - | - |
|---|
| Repayments of short-term borrowings from Merck & Co., Inc., net | 1,512 | - | - |
|---|
| Repayments of short-term borrowings from Merck & Co., Inc., net | 1,512 | - | - |
|---|
| Net consideration paid to Merck & Co. Inc. in connection with the Separation | 9,000 | - | - |
|---|
| Net consideration paid to Merck & Co. Inc. in connection with the Separation | 9,000 | - | - |
|---|
| Net transfers to Merck & Co., Inc. | -440 | 24 | - |
|---|
| Net transfers to Merck & Co., Inc. | -440 | 24 | - |
|---|
| Employee withholding taxes related to stock-based awards | - | 11 | 17 |
|---|
| Employee withholding taxes related to stock-based awards | - | 11 | 17 |
|---|
| Dividend payments | 145 | 290 | 294 |
|---|
| Dividend payments | 145 | 290 | 294 |
|---|
| Net Cash Flows Used in Financing Activities from Continuing Operations | -977 | -433 | -569 |
|---|
| Net Cash Flows Used in Financing Activities from Continuing Operations | -977 | -433 | -569 |
|---|
| Net Cash Provided by (Used in) Operating Activities | 298 | - | - |
|---|
| Net Cash Used in Financing Activities | -356 | - | - |
|---|
| Net Cash Used in Financing Activities | -356 | - | - |
|---|
| Net Cash Flows Used in Discontinued Operations | -58 | - | - |
|---|
| Net Cash Flows Used in Discontinued Operations | -58 | - | - |
|---|
| Effect of Exchange Rate Changes on Cash and Cash Equivalents from Continuing Operations | 23 | -36 | 17 |
|---|
| Net (Decrease) Increase in Cash and Cash Equivalents | 667 | -31 | -13 |
|---|
| Net (Decrease) Increase in Cash and Cash Equivalents | 667 | -31 | -13 |
|---|